|
|
CBP-12 |
|
Vaxjo ID |
245 |
|
Vaccine Adjuvant Name |
CBP-12 |
|
Alternative Names |
Clec9a Binding Peptide, 12-mer peptide vaccine carrier |
|
Adjuvant VO ID |
VO_0005732
|
|
Description |
A rationally designed 12-amino-acid peptide that binds specifically to Clec9a receptors on dendritic cells, enabling adjuvant-free peptide vaccine delivery for cancer immunotherapy |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
2-mer peptide carrier (CBP-12) with high affinity for Clec9a expressed on DCs was developed using an in silico rational optimization method. |
|
Structure |
A 12-amino-acid peptide with high affinity to Clec9a (sequence: WPRFHSSVRHTH), conjugated via GGG linker to antigens like OVA, gp100, or HPV E7 |
|
Preparation |
Synthesized by Fmoc solid-phase peptide synthesis; conjugated to antigens via linker (e.g., GGG), purified by RP-HPLC |
|
Dosage |
Typically 20 µg per mouse, injected subcutaneously weekly for 3 weeks |
|
Function |
A 12-mer peptide carrier (CBP-12) with high affinity for Clec9a expressed on DCs was developed using an in silico rational optimization method. The therapeutic effects of the adjuvant-free vaccine comprising CBP-12 and exogenous or endogenous antigenic peptides were investigated in terms of antigen cross-presentation efficacy, specific cytotoxic T lymphocyte response, and antitumor activity. It elicits both strong cytotoxic CD8+ T cell and antibody responses |
|
Safety |
Safe in mice; no endotoxin contamination, no systemic inflammation; did not induce IL-12 or TNF-α/IL-6 expression |
| References |
Chen et al., 2023: Chen S, Pounraj S, Sivakumaran N, Kakkanat A, Sam G, Kabir MT, Rehm BHA. Precision-engineering of subunit vaccine particles for prevention of infectious diseases. Frontiers in immunology. 2023; 14; 1131057. [PubMed: 36817419].
Gou et al., 2021: Gou S, Wang S, Liu W, Chen G, Zhang D, Du J, Yan Z, Wang H, Zhai W, Sui X, Wu Y, Qi Y, Gao Y. Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis. Theranostics. 2021; 11(15); 7308-7321. [PubMed: 34158852].
|
|
